Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: A critical review of quantitative data

Patient

Volumn 6, Issue 4, 2013, Pages 241-255

  Bewtra, Meenakshi ^a   Johnson, F Reed ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NATALIZUMAB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

ANUS FISTULA; BONE DISEASE; CATARACT; CLINICAL ASSESSMENT; COLON RESECTION; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FECES INCONTINENCE; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH SURVEY; HEPATOSPLENIC T CELL LYMPHOMA; HOSPITALIZATION; HUMAN; ILEAL POUCH ANAL ANASTOMOSIS; ILEOSTOMY; ILEUM BYPASS; ILEUM POUCH; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTESTINE CANCER; INTESTINE RESECTION; LONG TERM CARE; LYMPHOMA; MALNUTRITION; MEDICAL INFORMATION; MEDLINE; NEOPLASM; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; PATIENT CARE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PELVIS ABSCESS; PERIANAL ABSCESS; POSTOPERATIVE INFECTION; PREVALENCE; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUANTITATIVE STUDY; REMISSION; REVIEW; RISK ASSESSMENT; SEPSIS; SURGICAL RISK; SYSTEMATIC REVIEW; TREATMENT DURATION; TYPES OF STUDY; ULCERATIVE COLITIS; UTERINE CERVIX DYSPLASIA; WOUND DEHISCENCE;

DECISION MAKING; HUMANS; INFLAMMATORY BOWEL DISEASES; PATIENT PREFERENCE;

EID: 84890088486     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.1007/s40271-013-0031-2     Document Type: Review

References (140)

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-94.
2. Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am. 2004;33:303-17, ix-x.
3. Hanauer S, Sninsky C, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. The Mesalamine Study Group. Ann Intern Med. 1996;124:204-11.
4. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-85.
5. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis: a multicenter study. Ann Intern Med. 1991;115:350-5.
6. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993;88:1188-97.
7. Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002;97:1398-407.
8. Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137:1934-43.e1-3.
9. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-60.
10. Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 2007;7:13.
11. Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci. 2006;51:1833-40.
12. Michelassi F, Lee J, Rubin M, et al. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg 2003;238:433-41; discussion 442-5.
13. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2007;5:597-601.
14. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3-11.
15. Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol. 2001;96:1977-97.
16. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lemann score. Inflamm Bowel Dis. 2011;17:1415-22.
17. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010;139:1147-55.
18. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology. 2002;122:1808-14.
19. Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19:599-613.
20. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379-88.
21. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127:723-9.
22. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-95.
23. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology. 2011;140(1827-1837):e2.
24. McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2005;(2):CD000297.
25. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000;342:1627-32.
26. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2010;(6):CD000545.
27. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009;(1):CD000067.
28. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
29. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
30. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-38.
31. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-18.
32. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-25.
33. Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212-21.
34. Lichtenstein GR, Cohen R, Feagan BG, et al. Safety of infliximab and other Crohn's disease therapies: Treat™ Registry data with 24,575 patient-years of follow-up. Am J Gastroenterol. 2008;103.
35. Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 2008;103:1428-35; quiz 1436.
36. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin Gastroenterol Hepatol. 2006;4:621-30.
37. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-36.
38. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther. 2005;22:1-16.
39. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1017-24; quiz 976.
40. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
41. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol. 2009;10:816-24.
42. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009;104:2524-33.
43. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:631-6.
44. Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:598-605.
45. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-5.
46. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-81.
47. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146-53.
48. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-25.
49. Khan WA, Yu L, Eisenbrey AB, et al. Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients: report of two cases and review of literature. Am J Clin Pathol. 2001;116:41-50.
50. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386-8.
51. Moran G, Dillon J, Green J. Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree? Inflamm Bowel Dis. 2009;15:1281-2.
52. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-35.
53. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-13.
54. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76.
55. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-50.
56. Su C, Lichtenstein GR. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine. Gastroenterol Clin North Am 2004;33:209-34, viii.
57. Kaplan GG, McCarthy EP, Ayanian JZ, Korzenik J, Hodin R, Sands BE. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134:680-7.
58. Roberts SE, Williams JG, Yeates D, Goldacre MJ. Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies. BMJ. 2007;335:1033.
59. Alves A, Panis Y, Mathieu P, et al. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg 2005;140:278-83, discussion 284.
60. Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum. 2005;48:70-3.
61. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120-7.
62. Delaney CP, Fazio VW, Remzi FH, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg. 2003;238:221-8.
63. Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg. 2003;197:379-85.
64. Pal S, Sahni P, Pande GK, Acharya SK, Chattopadhyay TK. Outcome following emergency surgery for refractory severe ulcerative colitis in a tertiary care centre in India. BMC Gastroenterol. 2005;5:39.
65. Bach SP, Mortensen NJ. Ileal pouch surgery for ulcerative colitis. World J Gastroenterol. 2007;13:3288-300.
66. Sacristan JA. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Med Inform Decis Mak. 2013;13:6.
67. Truog RD. Patients and doctors: evolution of a relationship. N Engl J Med. 2012;366:581-5.
68. Laine C, Davidoff F. Patient-centered medicine: a professional evolution. JAMA. 1996;275:152-6.
69. Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51:1087-110.
70. Rademakers J, Delnoij D, Nijman J, de Boer D. Educational inequalities in patient-centred care: patients' preferences and experiences. BMC Health Serv Res. 2012;12:261
71. Bensing J. Bridging the gap. The separate worlds of evidence-based medicine and patient-centered medicine. Patient Educ Couns. 2000;39:17-25.
72. Mohamed AF, Hauber AB, Johnson FR, Coon CD. Patient preferences and linear scoring rules for patient-reported outcomes. Patient. 2010;3:217-27.
73. Bala MV, Zarkin GA. Are QALYs an appropriate measure for valuing morbidity in acute diseases? Health Econ. 2000;9:177-80.
74. Giesler RB, Ashton CM, Brody B, et al. Assessing the performance of utility techniques in the absence of a gold standard. Med Care. 1999;37:580-8.
75. O'Leary JF, Fairclough DL, Jankowski MK, Weeks JC. Comparison of time-tradeoff utilities and rating scale values of cancer patients and their relatives: evidence for a possible plateau relationship. Med Decis Making. 1995;15:132-7.
76. Lin MR, Yu WY, Wang SC. Examination of assumptions in using time tradeoff and standard gamble utilities in individuals with spinal cord injury. Arch Phys Med Rehabil. 2012;93:245-52.
77. Bleichrodt H, Pinto J. The validity of QALYs under non-expected utility. Econ J. 2005;115:533-50.
78. Brazier J, Rowen D, Yang Y, Tsuchiya A. Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale. Eur J Health Econ. 2012;13:575-87.
79. Hauber AB. Healthy-years equivalent: wounded but not yet dead. Expert Rev Pharmacoecon Outcomes Res. 2009;9:265-9.
80. Johnson FR. Editorial: moving the QALY forward or just stuck in traffic? Value Health. 2009;12(Suppl 1):S38-9.
81. Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health. 2009;12(Suppl 1):S10-5.
82. Wong S, Walker JR, Carr R, et al. The information needs and preferences of persons with longstanding inflammatory bowel disease. Can J Gastroenterol. 2012;26:525-31.
83. Conrad S, Huppe A, Raspe H. Preference of patients with inflammatory bowel disease regarding information and shared decision-making: results from a cross-sectional survey in Germany. Z Gastroenterol. 2012;50:364-72.
84. Bernstein KI, Promislow S, Carr R, Rawsthorne P, Walker JR, Bernstein CN. Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:590-8.
85. Siegel C, Schwartz L, Woloshin S, et al. When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflamm Bowel Disease. 2010;16:1658-62.
86. Baars J, Siegel C, van't Spijker A, Markus T, Kuipers E, van der Woude C. Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. Dig Liver Dis 2010;42:777-84.
87. Allen PB, Lindsay H, Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 2010;10:1
88. Lewis JR, Konda V, Rubin DT. Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers. 2009;13:495-503.
89. Gray JR, Leung E, Scales J. Treatment of ulcerative colitis from the patient's perspective: a survey of preferences and satisfaction with therapy. Aliment Pharmacol Ther. 2009;29:1114-20.
90. Knopf JM, Hornung RW, Slap GB, DeVellis RF, Britto MT. Views of treatment decision making from adolescents with chronic illnesses and their parents: a pilot study. Health Expect. 2008;11:343-54.
91. Kennedy ED, To T, Steinhart AH, Detsky A, Llewellyn-Thomas HA, McLeod RS. Do patients consider postoperative maintenance therapy for Crohn's disease worthwhile? Inflamm Bowel Dis. 2008;14:224-35.
92. Konda V, Huo D, Hermes G, Liu M, Patel R, Rubin DT. Do patients with inflammatory bowel disease want genetic testing? Inflamm Bowel Dis. 2006;12:497-502.
93. Rutter MD, Saunders BP, Wilkinson KH, Schofield G, Forbes A. Intangible costs and benefits of ulcerative colitis surveillance: a patient survey. Dis Colon Rectum. 2006;49:1177-83.
94. Cheung WY, Dove J, Lervy B, Russell IT, Williams JG. Shared care in gastroenterology: GPs' views of open access to out-patient follow-up for patients with inflammatory bowel disease. Fam Pract. 2002;19:53-6.
95. Green TJ, Issenman RM, Jacobson K. Patients' diets and preferences in a pediatric population with inflammatory bowel disease. Can J Gastroenterol. 1998;12:544-9.
96. Probert CS, Mayberry JF. Inflammatory bowel disease: patients' expectations in the 1990s. J R Soc Med. 1991;84:131-2.
97. Johnson FR, Hauber AB, Osoba D, Hsu MA, Coombs J, Copley-Merriman C. Are chemotherapy patients' HRQoL importance weights consistent with linear scoring rules? A stated-choice approach. Qual Life Res. 2006;15:285-98.
98. Siegel CA, Levy LC, Mackenzie TA, Sands BE. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1-6.
99. Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4:1135-42.
100. McLeod RS, Churchill DN, Lock AM, Vanderburgh S, Cohen Z. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology. 1991;101:1307-13.
101. Kennedy ED, Detsky AS, Llewellyn-Thomas HA, et al. Can the standard gamble be used to determine utilities for uncertain health states? An example using postoperative maintenance therapy in Crohn's disease. Med Decis Mak. 2000;20:72-8.
102. Arseneau KO, Cohn SM, Cominelli F, Connors AF Jr. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology. 2001;120:1640-56.
103. Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn's disease. Dis Colon Rectum. 2007;50:586-97.
104. Waljee AK, Higgins PD, Waljee JF, et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol. 2011;106:794-9.
105. Waljee AK, Morris AM, Waljee JF, Higgins PD. Individual health discount rate in patients with ulcerative colitis. Inflamm Bowel Dis. 2011;17:1328-32.
106. Brown LK, Waljee AK, Higgins PD, Waljee JF, Morris AM. Proximity to disease and perception of utility: physicians' vs patients' assessment of treatment options for ulcerative colitis. Dis Colon Rectum. 2011;54:1529-36.
107. Leshno M. On using the standard gamble to determine utilities for uncertain health states. Med Decis Making. 2001;21:82-3.
108. Deaton A, Muellbauer J. Economics and consumer behavior. Cambridge, UK: Cambridge University Press; 1980.
109. Starmer C. Developments in non-expected utility theory: the hunt for a descriptive theory of choice under risk. J Econ Lit. 2000;38:332-82.
110. Van Houtven G, Johnson FR, Kilambi V, Hauber AB. Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis. Med Decis Mak. 2011;31:469-80.
111. Apter AJ, Paasche-Orlow MK, Remillard JT, et al. Numeracy and communication with patients: they are counting on us. J Gen Intern Med. 2008;23:2117-24.
112. Fagerlin A, Ubel PA, Smith DM, Zikmund-Fisher BJ. Making numbers matter: present and future research in risk communication. Am J Health Behav. 2007;31(Suppl 1):S47-56.
113. Elting LS, Martin CG, Cantor SB, Rubenstein EB. Influence of data display formats on physician investigators' decisions to stop clinical trials: prospective trial with repeated measures. BMJ. 1999;318:1527-31.
114. Reyna VF, Brainerd CJ. Numeracy, ratio bias, and denominator neglect in judgments of risk and probability. Learn Individ Differ. 2008;18:89-107.
115. Ancker JS, Senathirajah Y, Kukafka R, Starren JB. Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc. 2006;13:608-18.
116. Garcia-Retamero R, Galesic M. Communicating treatment risk reduction to people with low numeracy skills: a cross-cultural comparison. Am J Public Health. 2009;99:2196-202.
117. Burkell J. What are the chances? Evaluating risk and benefit information in consumer health materials. J Med Libr Assoc. 2004;92:200-8.
118. Brase GL. Which statistical formats facilitate what decisions? The perception and influence of different statistical information formats. J Behav Decis Mak. 2002;15:381-401.
119. Yamagishi K. When a 12.86% mortality is more dangerous then 24.14%: implications for risk communication. Appl Cogn Psychol. 1997;11:495-506.
120. Galesic M, Gigerenzer G, Straubinger N. Natural frequencies help older adults and people with low numeracy to evaluate medical screening tests. Med Decis Mak. 2009;29:368-71.
121. Cavanaugh K, Wallston KA, Gebretsadik T, et al. Addressing literacy and numeracy to improve diabetes care: two randomized controlled trials. Diabetes Care. 2009;32:2149-55.
122. Fagerlin A, Wang C, Ubel PA. Reducing the influence of anecdotal reasoning on people's health care decisions: is a picture worth a thousand statistics? Med Decis Mak. 2005;25:398-405.
123. Hawley ST, Zikmund-Fisher B, Ubel P, Jancovic A, Lucas T, Fagerlin A. The impact of the format of graphical presentation on health-related knowledge and treatment choices. Patient Educ Couns. 2008;73:448-55.
124. Fagerlin A, Zikmund-Fisher BJ, Ubel PA, Jankovic A, Derry HA, Smith DM. Measuring numeracy without a math test: development of the Subjective Numeracy Scale. Med Decis Mak. 2007;27:672-80.
125. Woloshin S, Schwartz LM, Moncur M, Gabriel S, Tosteson AN. Assessing values for health: numeracy matters. Med Decis Mak. 2001;21:382-90.
126. Zikmund-Fisher BJ, Smith DM, Ubel PA, Fagerlin A. Validation of the Subjective Numeracy Scale: effects of low numeracy on comprehension of risk communications and utility elicitations. Med Decis Mak. 2007;27:663-71.
127. Johnson FR, Banzhaf MR, Desvousges WH. Willingness to pay for improved respiratory and cardiovascular health: a multiple-format, stated-preference approach. Health Econ. 2000;9:295-317.
128. Phillips KA, Maddala T, Johnson FR. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res. 2002;37:1681-705.
129. Ryan M, Hughes J. Using conjoint analysis to assess women's preferences for miscarriage management. Health Econ. 1997;6:261-73.
130. Hauber AB, Johnson FR, Grotzinger KM, Ozdemir S. Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies. Ann Pharmacother. 2010;44:479-88.
131. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol. 2009;256:554-62.
132. Johnson FR, Ozdemir S, Hauber B, Kauf TL. Women's willingness to accept perceived risks for vasomotor symptom relief. J Womens Health (Larchmt). 2007;16:1028-40.
133. Johnson FR, Manjunath R, Mansfield CA, Clayton LJ, Hoerger TJ, Zhang P. High-risk individuals' willingness to pay for diabetes risk-reduction programs. Diabetes Care. 2006;29:1351-6.
134. Lichtenstein G, Waters H, Kelly J, et al. Assessing drug treatment preferences of patients with Crohn's disease, a conjoint analysis. Patient. 2010;3:113-23.
135. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133:769-79.
136. Johnson FR, Ozdemir S, Mansfield C, Hass S, Siegel CA, Sands BE. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009;29:121-36.
137. Johnson FR, Hauber B, Ozdemir S, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm. 2010;16:616-28.
138. Hodgkins P, Swinburn P, Solomon D, Yen L, Dewilde S, Lloyd A. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Patient. 2012;5:33-44.
139. Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403-13.
140. Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16:3-13.